NASDAQ:VIVE Viveve Medical (VIVE) Stock Price, News & Analysis → The new masters of energy (From Porter & Company) (Ad) Free VIVE Stock Alerts $0.0003 0.00 (0.00%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$0.0003▼$0.000350-Day Range N/A52-Week Range$0.00▼$0.11Volume3,855 shsAverage Volume3,345 shsMarket Capitalization$3,216.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsStock AnalysisChartCompetitorsFinancialsSEC FilingsTrends Get Viveve Medical alerts: Email Address Ad Augury ResearchBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is currently auctioning off CITGO (the winning bid will be announced on July 22nd).Get all the details here. About Viveve Medical Stock (NASDAQ:VIVE)Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.Read More VIVE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIVE Stock News HeadlinesApril 17, 2024 | finance.yahoo.com5-Alpha Reductase Deficiency Global Market Report 2024: A $1.94 Billion Projected Market in 2028April 15, 2024 | finance.yahoo.comInMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTLFebruary 23, 2024 | benzinga.comViveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, PredictionsJuly 29, 2023 | seekingalpha.comVIVE Viveve Medical, Inc.July 25, 2023 | finance.yahoo.comInMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve PatentsJune 14, 2023 | uk.finance.yahoo.comVIVE - Viveve Medical, Inc.February 24, 2023 | finance.yahoo.comViveve Medical, Inc. (VIVE)January 17, 2023 | msn.comWhy Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionJanuary 17, 2023 | finanznachrichten.deViveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceJanuary 17, 2023 | seekingalpha.comViveve crashes ~60% as company decides to delist, explore sale after trial failsJanuary 17, 2023 | finance.yahoo.comViveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceJanuary 17, 2023 | finance.yahoo.comViveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence TrialJanuary 17, 2023 | investorplace.comWhy Is Viveve Medical (VIVE) Stock Down 69% Today?December 29, 2022 | insidermonkey.comViveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call TranscriptDecember 15, 2022 | finance.yahoo.comViveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits ConcludedDecember 1, 2022 | finanznachrichten.deViveve Medical, Inc.: Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceDecember 1, 2022 | finance.yahoo.comViveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceNovember 13, 2022 | finance.yahoo.comViveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 10, 2022 | finanznachrichten.deViveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comViveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 27, 2022 | finance.yahoo.comViveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022October 25, 2022 | finance.yahoo.comGlobal Cosmetic Gynecology Market Report to 2027 - Featuring Alma Laser, Lutronic, Viveve Medical and Venus Concept Among OthersOctober 13, 2022 | forbes.comViveve MedicalOctober 4, 2022 | finanznachrichten.deViveve Medical, Inc.: Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceOctober 4, 2022 | finance.yahoo.comViveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceSee More Headlines Receive VIVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viveve Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today6/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:VIVE Previous SymbolOTCMKTS:PLCSD CUSIPN/A CIK879682 Webwww.viveve.com Phone(720) 696-8100Fax720-696-8199Employees47Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares10,720,000Free Float10,110,000Market Cap$3,216.00 OptionableNot Optionable Beta0.44 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Jim B. Robbins (Age 60)Senior VP of Finance & Administration and Principal Accounting & Financial Officer Comp: $386.94kMs. Deborah Ann Jorn M.B.A. (Age 66)Senior Advisor to the CEO & Director Comp: $35kMr. Martin Kerber P.E.Vice President of Research, Development & OperationsMs. Jeannie SwindleSenior Director of Corporate CommunicationsMr. Jeff SinclairVice President of International SalesMr. Gary KaiserVice President of Global MarketingMs. Lori McMillanVice President of Human ResourcesMs. Suzon D. Lommel (Age 66)Senior Vice President of Regulatory & Quality Affairs More ExecutivesKey CompetitorsHologicNASDAQ:HOLXMedtronicNYSE:MDTMasimoNASDAQ:MASITransMedics GroupNASDAQ:TMDXIntegerNYSE:ITGRView All Competitors VIVE Stock Analysis - Frequently Asked Questions How have VIVE shares performed in 2024? Viveve Medical's stock was trading at $0.0002 at the beginning of 2024. Since then, VIVE shares have increased by 50.0% and is now trading at $0.0003. View the best growth stocks for 2024 here. How were Viveve Medical's earnings last quarter? Viveve Medical, Inc. (NASDAQ:VIVE) posted its earnings results on Thursday, November, 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.09. The business had revenue of $1.62 million for the quarter. During the same period in the prior year, the company earned ($2.60) EPS. What other stocks do shareholders of Viveve Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Viveve Medical investors own include Corbus Pharmaceuticals (CRBP), Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), SCYNEXIS (SCYX), Western Digital (WDC), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Novavax (NVAX). When did Viveve Medical IPO? Viveve Medical (VIVE) raised $13 million in an initial public offering (IPO) on Tuesday, June 14th 2016. The company issued 1,600,000 shares at $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager. How do I buy shares of Viveve Medical? Shares of VIVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIVE) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viveve Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viveve Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.